Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus monotherapy in low-risk kidney transplant recipients
NL-OMON26543Recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2014
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tacrolimus and mycophenolate mofetil in kidney allograft rejection (2 arms), sponsored by Erasmus MC. Primary endpoints: Biological plausibility composite feasibility endpoint, Consent rate and 1 more. Started Sep 2014; status: recruiting.
02
Drugs
tacrolimusmycophenolate mofetil
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on NL-OMON26543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26543.